The San Clemente, Calif.-based company said it plans to float 1.2 million shares of its common stock at $2.05 per share. The offering also includes unregistered warrants to purchase an additional 1.2 million shares at approximately 13¢ per warrant, which the company said could bring in an additional $150,000.
Funds from the placement are slated to support continued commercialization, clinical and product development activities and for general corporate purposes, ReShape Lifesciences said.
The offering is expected to close on July 12, ReShape said. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering, according to a press release.
Last month, ReShape Lifesciences said it inked approximately $1.5 million in offering deals with a number of institutional investors.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.